Global Health Updates: Breakthroughs, Outbreaks, and IPOs

The latest health news includes a bluetongue outbreak in Norway, Zenas BioPharma's massive US IPO, and a new AI tool for diagnosing heart failure. Other notable updates involve GSK's asthma drug success, the spread of counterfeit Ozempic, and Congo receiving its first mpox vaccine doses to combat the outbreak.

This week in health, several critical updates have emerged, indicating both challenges and advancements in various health sectors worldwide.

Norway has reported a concerning outbreak of bluetongue disease among sheep, a highly deadly condition for ruminants, prompting a new wave of vaccinations. Meanwhile, Zenas BioPharma, backed by Bristol-Myers Squibb, is eyeing a hefty $689.7 million valuation with its US IPO, aiming to raise substantial funds for the development of immunology-based therapies.

In lighter news, researchers have leveraged a dye to make mouse skin transparent, aiding in the study of internal structures. The CDC has confirmed a human case of bird flu in Missouri, while the US ramps up mpox testing and vaccine access. GSK's asthma drug Nucala has met primary study goals for treating COPD. Additionally, the Congo has received crucial mpox vaccine doses. In other news, counterfeit Ozempic has surfaced, causing alert among those seeking weight-loss treatments.

(With inputs from agencies.)